Boston Scientific stock holds steady as Oppenheimer cuts price target to USD 65

Published on 09/21/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock traded around USD 43.34 on September 21, 2026, about 18 % below its 52-week high of USD 52.65 on the NYSE. Oppenheimer now targets USD 65 per share while Zacks assigns a Strong Sell rating based on softer earnings estimates.

Sterile Fertigungslinie für Herzkathetersysteme in einem Medizintechnik-Reinraum in Marlborough MA — Boston Scientific Corp. betreibt sterile Reinraumfertigung für Herzkathetersysteme am Standort Marlborough MA, ISIN US10117L1017, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US10117L1017) changed hands at USD 43.34 on the New York Stock Exchange as of September 21, 2026, leaving the shares about 18 % below a recent 52-week high of USD 52.65 and close to the lower end of their trading range for the past year. According to CNBC on September 21, 2026, the stock closed the previous session at USD 43.34, with a 52-week range between USD 42.20 and USD 55.65 and a trading volume of roughly 24,6 million shares.

Oppenheimer trims price target but keeps Outperform

A key catalyst on September 21, 2026 is a fresh rating update from Oppenheimer, which continues to see upside in Boston Scientific despite lowering its valuation bar. As TradingView reported on September 21, 2026, Oppenheimer reiterated its Outperform rating on Boston Scientific while setting a new price target of USD 65 per share.

Further detail on the change in view comes from a report on the Hong Kong based platform Futu. According to Futu News on September 21, 2026, analyst Suraj Kalia at Oppenheimer maintained a Buy rating but reduced the price target from USD 85 to USD 65, implying a cut of USD 20 or around 24 % in the long term valuation benchmark.

Earnings momentum and valuation under scrutiny

Beyond the single analyst move, earnings expectations and valuation are also shaping sentiment around Boston Scientific. According to a sector comparison by Zacks on September 21, 2026, the consensus estimate for Boston Scientific's 2026 earnings per share stands at USD 3.29, which would represent a 7.5 % increase compared with the prior year if achieved.

However, Zacks highlights that earnings expectations have been drifting lower. The same overview notes that the 2026 EPS estimate declined by 1.8 % over the past 60 days, and that Boston Scientific carries a Zacks Rank 5, which corresponds to a Strong Sell rating in their system. In the medium term, that combination of still growing earnings and downward revisions suggests that investors are weighing execution risks more heavily even as they continue to pay a premium multiple for the stock.

Zacks also flags valuation as a potential constraint. As described by Zacks on September 21, 2026, Boston Scientific trades at a forward five year price to sales ratio of 2.85, compared with an industry average around 2.11, indicating that the stock is valued at roughly 35 % above its peers on that metric.

Latest reported revenue and profit metrics

The most recent quarterly figures show that Boston Scientific is still delivering solid growth from its diversified medical technology portfolio. Price data on Yahoo Finance on September 21, 2026 indicate that in the second quarter of fiscal year 2026, Boston Scientific generated revenue of approximately USD 5.44 billion and earnings of about USD 907 million.

The same data set shows that the company achieved a profit margin of 16.67 % in that quarter. Relative to the prior year period, this implies a meaningful expansion in profitability, as Boston Scientific has historically reported margins in the low to mid teens, so the Q2 fiscal 2026 reading is several percentage points higher than earlier periods even if the exact prior margin is not specified in the overview.

On a per share basis, Yahoo Finance's consensus and actuals section shows that Boston Scientific delivered non GAAP earnings per share of USD 0.86 for the second quarter of fiscal 2026, compared with a consensus estimate of USD 0.83 for the period. That means the company beat expectations by USD 0.03 per share for the quarter, or roughly 3.6 % above the analyst forecast.

Market position and risk balance

For investors, the current setup in Boston Scientific combines a healthy fundamental trajectory with more cautious external views. The stock price around USD 43.34 as of September 21, 2026 sits well below Oppenheimer's reduced USD 65 target, giving potential upside of more than 40 % if the brokerage's view proves correct, but Zacks' Strong Sell stance and premium valuation multiple point to the risk that any disappointment in product launches or procedure volumes could pressure the shares further.

In particular, Zacks emphasizes that existing Boston Scientific holders may consider exiting positions until operational visibility improves, highlighting that Medtronic, a key competitor in electrophysiology, currently carries a more neutral Rank 3 Hold rating in their framework. That contrast underscores how stock specific factors, including product launch timing and margin execution, may be driving a wedge between companies in the same subsegment of medical devices.

Boston Scientific stock at a glance

As of the latest completed session on September 21, 2026, Boston Scientific stock closed at USD 43.34 on the New York Stock Exchange, after an intraday move that left the shares modestly lower compared with the prior close and within a 52-week range of USD 42.20 to USD 55.65 in USD terms. On the same day, the shares changed hands in heavy volume of roughly 24.6 million units, indicating robust liquidity for both institutional and retail investors.